Insurance rarely reimburses experimental stem cell therapy for developmental delay outside clinical trial enrolment. Paediatric disability insurance in most Western countries covers conventional therapies (physiotherapy, special education, behavioural intervention) but excludes investigational cell therapy. Some families have pursued insurance coverage in trial settings by demonstrating medical necessity, but success is inconsistent. Out-of-pocket expense is the default expectation.
Treatments for developmental delay cost €4,500–7,500 per protocol in specialised neurodevelopmental centres. Neurogenic cell therapies command higher costs (€6,500–8,000) due to manufacturing complexity and regulatory oversight. Placental MSC infusions are moderately priced (€4,500–6,000). Most protocols involve 2–4 infusions over 6–12 months. No paediatric insurance scheme reimburses cell therapy for cognitive delay outside experimental frameworks. Families bear full out-of-pocket expense, creating significant access barriers in lower-income regions.
Am I a candidate? → · Developmental Cognitive Delay: full overview → · Developmental Cognitive Delay cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment